Mirae Asset Global Investments Co. Ltd. Buys 205,942 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Mirae Asset Global Investments Co. Ltd. increased its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 1,052.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 225,506 shares of the company’s stock after acquiring an additional 205,942 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.09% of Lyell Immunopharma worth $437,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LYEL. SG Americas Securities LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter valued at $80,000. Exchange Traded Concepts LLC grew its position in Lyell Immunopharma by 41.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 61,920 shares of the company’s stock valued at $91,000 after purchasing an additional 18,183 shares during the period. TD Asset Management Inc grew its position in Lyell Immunopharma by 112.1% in the 3rd quarter. TD Asset Management Inc now owns 916,232 shares of the company’s stock valued at $1,347,000 after purchasing an additional 484,316 shares during the period. Principal Financial Group Inc. grew its position in Lyell Immunopharma by 13.2% in the 3rd quarter. Principal Financial Group Inc. now owns 68,080 shares of the company’s stock valued at $100,000 after purchasing an additional 7,915 shares during the period. Finally, Ieq Capital LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter valued at $121,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

LYEL opened at $2.17 on Friday. The company has a market capitalization of $553.22 million, a price-to-earnings ratio of -2.33 and a beta of -0.56. The firm’s fifty day moving average price is $2.33 and its two-hundred day moving average price is $2.04. Lyell Immunopharma, Inc. has a 1 year low of $1.32 and a 1 year high of $3.97.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. As a group, equities analysts anticipate that Lyell Immunopharma, Inc. will post -0.84 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, February 29th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.